Abstract: The present invention relates to a method for producing an InP-based quantum dot precursor from a phosphorus source and an indium source, in which a silylphosphine compound represented by the following Formula (1) with a content of a compound represented by the following Formula (2) of 0.3 mol % or less is used as the phosphorus source. Further, the present invention provides a method for producing an InP-based quantum dot comprising heating an InP quantum dot precursor to a temperature of 200° C. or more and 350° C. or less to obtain an InP quantum dot. (R is as defined in the specification.

Abstract: The silyl phosphine compound of the present invention is represented by the formula (1) and has an arsenic content of not more than 1 ppm. The process for producing a silyl phosphine compound of the present invention is a process comprising mixing a basic compound, a silylating agent and phosphine to obtain a solution containing a silyl phosphine compound, removing a solvent from the solution to obtain a concentrated solution of a silyl phosphine compound, and distilling the concentrated solution, wherein an arsenic content in the phosphine is adjusted to not more than 1 ppm by volume in terms of arsine. The process for producing InP quantum dots of the present invention uses, as a phosphorus source, a silyl phosphine compound represented by the formula (1) and having an arsenic content of not more than 1 ppm by mass. (For definition of R, see the specification.

Abstract: The silyl phosphine compound of the present invention is represented by the formula (1) and has an arsenic content of not more than 1 ppm. The process for producing a silyl phosphine compound of the present invention is a process comprising mixing a basic compound, a silylating agent and phosphine to obtain a solution containing a silyl phosphine compound, removing a solvent from the solution to obtain a concentrated solution of a silyl phosphine compound, and distilling the concentrated solution, wherein an arsenic content in the phosphine is adjusted to not more than 1 ppm by volume in terms of arsine. The process for producing InP quantum dots of the present invention uses, as a phosphorus source, a silyl phosphine compound represented by the formula (1) and having an arsenic content of not more than 1 ppm by mass. (For definition of R, see the specification.

Abstract: The present invention relates to a method for producing an InP-based quantum dot precursor from a phosphorus source and an indium source, in which a silylphosphine compound represented by the following Formula (1) with a content of a compound represented by the following Formula (2) of 0.3 mol % or less is used as the phosphorus source. Further, the present invention provides a method for producing an InP-based quantum dot comprising heating an InP quantum dot precursor to a temperature of 200° C. or more and 350° C. or less to obtain an InP quantum dot. (R is as defined in the specification.

Abstract: A method for producing an indium carboxylate of the present invention comprises the steps of reacting a hydroxyl group-containing indium carboxylate represented by Formula (1): In(RCOO)3-x(OH)x, wherein R is a straight chain or branched chain aliphatic group having 0 to 5 carbon atoms, and x is a number more than 0 and less than 3, with a lower carboxylic acid represented by the following Formula (2): R?COOH, wherein R? is a hydrogen atom or a straight chain or branched chain aliphatic group having 1 to 5 carbon atoms, and the hydrogen atom in the aliphatic group may be replaced with a halogen atom, so as to obtain a product; and then reacting the product with a higher carboxylic acid having 12 or more carbon atoms.

Abstract: The phosphine transition metal complex of the present invention is represented by formula (1). Preferably, R1 and R6 are identical groups, R2 and R7 are identical groups, R3 and R8 are identical groups, R4 and R9 are identical groups, R5 and R10 are identical groups, and n and y are identical numbers. The phosphine transition metal complex is suitably obtained by reacting a phosphine derivative represented by formula (2) and a phosphine derivative represented by formula (3) with a salt of a transition metal of gold, copper or silver. See the description for the meanings of the symbols in each formula.

Abstract: The phosphine transition metal complex of the present invention is represented by formula (1). Preferably, R1 and R6 are identical groups, R2 and R7 are identical groups, R3 and R8 are identical groups, R4 and R9 are identical groups, R5 and R10 are identical groups, and n and y are identical numbers. The phosphine transition metal complex is suitably obtained by reacting a phosphine derivative represented by formula (2) and a phosphine derivative represented by formula (3) with a salt of a transition metal of gold, copper or silver. See the description for the meanings of the symbols in each formula.

Abstract: The silyl phosphine compound of the present invention is represented by the formula (1) and has an arsenic content of not more than 1 ppm. The process for producing a silyl phosphine compound of the present invention is a process comprising mixing a basic compound, a silylating agent and phosphine to obtain a solution containing a silyl phosphine compound, removing a solvent from the solution to obtain a concentrated solution of a silyl phosphine compound, and distilling the concentrated solution, wherein an arsenic content in the phosphine is adjusted to not more than 1 ppm by volume in terms of arsine. The process for producing InP quantum dots of the present invention uses, as a phosphorus source, a silyl phosphine compound represented by the formula (1) and having an arsenic content of not more than 1 ppm by mass. (For definition of R, see the specification.

Abstract: The anti-cancer agent of the present invention contains at least one kind of phosphine transition metal complex selected from a group of compounds represented by the following Formulae (1a) to (1d). According to this anti-cancer agent, an anti-cancer agent is provided which has a higher anti-cancer activity and lower toxicity compared to anti-cancer agents in the related art. In Formulae (1a), (1b), (1c), and (1d), R1 and R2 represent a linear or branched alkyl group, and R1 has a higher priority than R2 as ranked according to RS notation. R3 and R4 represent a hydrogen atom or a linear or branched alkyl group. M represents an atom of a transition metal selected from a group consisting of gold, copper, and silver. X? represents an anion.

Abstract: The anti-cancer agent of the present invention contains at least one kind of phosphine transition metal complex selected from a group of compounds represented by the following Formulae (1a) to (1d). According to this anti-cancer agent, an anti-cancer agent is provided which has a higher anti-cancer activity and lower toxicity compared to anti-cancer agents in the related art. In Formulae (1a), (1b), (1c), and (1d), R1 and R2 represent a linear or branched alkyl group, and R4 has a higher priority than R2 as ranked according to RS notation. R3 and R4 represent a hydrogen atom or a linear or branched alkyl group. M represents an atom of a transition metal selected from a group consisting of gold, copper, and silver. X? represents an anion.

Abstract: An anticancer agent having a novel chemical structure and high anticancer activity is provided. A phosphine transition metal complex of general formula (1) and an anticancer agent containing the complex are disclosed. R1 and R2, which may be the same or different, each represent a group having 1 to 10 carbon atoms selected from a straight-chain or branched alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an adamantyl group, a phenyl group, and a substituted phenyl group; R3 and R4, which may be the same or different, each represent a hydrogen atom, a straight-chain alkyl group having 1 to 6 carbon atoms or branched alkyl group having 1 to 6 carbon atoms; or R3 and R4 are taken together to form a saturated or unsaturated ring which may have a substituted group; M represents a transition metal atom selected from the group consisting of gold, copper, and silver; and X? represents an anion.

Abstract: There is provided a novel transition metal phosphine complex having excellent anticancer activity. The transition metal phosphine complex is represented by general formula (1): (wherein R1s and R3s each represent an alkyl group, a cycloalkyl group, an aryl group, an aralkyl group, a pyridyl group, or a pyrimidyl group; R2s and R4s each represent an alkyl group or a cycloalkyl group, provided that each R1 and each R2 are not the same group and that each R3 and each R4 are not the same group; As each represent a linear alkylene group or a cis-vinylene group; M represents a gold atom, a silver atom, a copper atom, or a platinum atom; and B represents an anionic species).

Abstract: An anticancer agent having a novel chemical structure and high anticancer activity is provided. A phosphine transition metal complex of general formula (1) and an anticancer agent containing the complex are disclosed. R1 and R2, which may be the same or different, each represent a group having 1 to 10 carbon atoms selected from a straight-chain or branched alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an adamantyl group, a phenyl group, and a substituted phenyl group; R3 and R4, which may be the same or different, each represent a hydrogen atom, a straight-chain alkyl group having 1 to 6 carbon atoms or branched alkyl group having 1 to 6 carbon atoms; or R3 and R4 are taken together to form a saturated or unsaturated ring which may have a substituted group; M represents a transition metal atom selected from the group consisting of gold, copper, and silver; and X? represents an anion.

Abstract: A phosphine transition metal complex is expressed by general formula (1): wherein A represents a groups selected from among alkylene, phenylene, and cis-vinylene; M represents an atom selected from the group consisting of gold, silver, copper, and platinum; B1 and B2 each represent a substituted or unsubstituted heterocyclic group containing a trivalent phosphorus atom forming a covalent bond with A and coordinating with M; and C represents an anionic atom.

Abstract: A phosphine transition metal complex is expressed by general formula (1): wherein A represents a groups selected from among alkylene, phenylene, and cis-vinylene; M represents an atom selected from the group consisting of gold, silver, copper, and platinum; B1 and B2 each represent a substituted or unsubstituted heterocyclic group containing a trivalent phosphorus atom forming a covalent bond with A and coordinating with M; and C represents an anionic atom.

Abstract: There is provided a novel transition metal phosphine complex having excellent anticancer activity. The transition metal phosphine complex is represented by general formula (1): (wherein R1s and R3s each represent an alkyl group, a cycloalkyl group, an aryl group, an aralkyl group, a pyridyl group, or a pyrimidyl group; R2s and R4s each represent an alkyl group or a cycloalkyl group, provided that each R1 and each R2 are not the same group and that each R3 and each R4 are not the same group; As each represent a linear alkylene group or a cis-vinylene group; M represents a gold atom, a silver atom, a copper atom, or a platinum atom; and B represents an anionic species).

Abstract: An anti-cancer agent contains a phosphine transition metal complex having a ferrocene skeleton, the complex being represented by general formula (3) below: (wherein R1, R2, R3, and R4 each represent a linear or branched alkyl group, a cycloalkyl group, an alkoxy group, an aryl group, or an aralkyl group; A represents a linear or branched alkyl group, a phenyl group, or a hydrogen atom; M1 represents a transition metal atom selected from the group consisting of gold, copper, platinum, and silver; and X1 represents an anion).